GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CytoSorbents Corp (NAS:CTSO) » Definitions » Total Current Liabilities

CytoSorbents (CytoSorbents) Total Current Liabilities : $13.42 Mil (As of Mar. 2024)


View and export this data going back to 2005. Start your Free Trial

What is CytoSorbents Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. CytoSorbents's total current liabilities for the quarter that ended in Mar. 2024 was $13.42

CytoSorbents Total Current Liabilities Historical Data

The historical data trend for CytoSorbents's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytoSorbents Total Current Liabilities Chart

CytoSorbents Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.94 10.15 13.69 9.72 14.55

CytoSorbents Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.44 10.35 11.97 14.55 13.42

CytoSorbents Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

CytoSorbents's Total Current Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=10.291+2.874
+Other Current Liabilities+Current Deferred Liabilities
=-1.7763568394003E-15+1.381
=14.55

CytoSorbents's Total Current Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=10.531+2.893
+Other Current Liabilities+Current Deferred Liabilities
=0+0
=13.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

CytoSorbents Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of CytoSorbents's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

CytoSorbents (CytoSorbents) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CytoSorbents Corp (NAS:CTSO) » Definitions » Total Current Liabilities
Comparable Companies
AXDX LUCD NSPR RTGN EAR XAIR RBOT ELUT ICCM NVNO ABT SYK MDT BSX SZSE:300760 DXCM EW ZBH STE XAMS:PHIA
Traded in Other Exchanges
HQE1:Germany
Address
305 College Road East, Princeton, NJ, USA, 08540
Website
https://www.cytosorbents.com
CytoSorbents Corp is involves in the treatment of life-threatening conditions in the intensive care (ICU) and cardiac surgery using blood purification via proprietary polymer adsorption technology. It has a number of products commercialized and in development based on this technology platform.
Executives
Edward Raymond Jones director 70 HOGAN LANE, AMBLER PA 19002
Kathleen P. Bloch officer: Chief Financial Officer 3 PERSHING COURT, NORTH BRUNSWICK NJ 08902
Vincent Capponi officer: Chief Operating Officer MEDASORB TECHNOLOGIES, 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852
Phillip P. Chan director, officer: President and CEO 1001 BRIGGS ROAD, SUITE 280, MOUNT LAUREL NJ 08054
Efthymios Deliargyris officer: Chief Medical Officer C/O PLX PHARMA,INC.8285 EL RIO STREET, SUITE 210, HOUSTON TX 77054
Jiny Kim director C/O CYTOSORBENTS CORPORATION, 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852
Alan D. Sobel director 293 EISENHOWER PARKWAY, LIVINGSTON NJ 07039
Michael G. Bator director C/O CYTOSORBENTS CORP., 7 DEER PARK DR., SUITE K, MONMOUTH JUNCTION NJ 08852
Alex D'amico officer: Chief Financial Officer 10 EAST PASSAIC AVENUE, UNIT C-2, NUTLEY NJ 07110
Al Kraus director MEDASORB TECHNOLOGIES, 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852
Eric R. Mortensen officer: Chief Medical Officer C/O CYTOSORBENTS CORPORATION, 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852
Njtc Investment Fund, Lp 10 percent owner 1001 BRIGGS ROAD, SUITE 280, MOUNT LAUREL NJ 08054
Robert Shipley 10 percent owner 9 NOBLE ROAD, NOGALES AZ 85621
Ronald Berger officer: See Remarks 7 DEERPARK DRIVE, STE K, MONMOUTH JUNCTION NJ 08852
Thomas Bocchino officer: Chief Financial Officer C/O CYTOSORBENTS CORP., 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852